RU2011101536A - Усовершенствованные пептидные медиаторы оттока холестерина - Google Patents

Усовершенствованные пептидные медиаторы оттока холестерина Download PDF

Info

Publication number
RU2011101536A
RU2011101536A RU2011101536/15A RU2011101536A RU2011101536A RU 2011101536 A RU2011101536 A RU 2011101536A RU 2011101536/15 A RU2011101536/15 A RU 2011101536/15A RU 2011101536 A RU2011101536 A RU 2011101536A RU 2011101536 A RU2011101536 A RU 2011101536A
Authority
RU
Russia
Prior art keywords
polypeptide
group
polypeptide according
mammal
peptidomimetic
Prior art date
Application number
RU2011101536/15A
Other languages
English (en)
Russian (ru)
Inventor
Джон К. БИЛИКИ (US)
Джон К. БИЛИКИ
Ян ЙОХАНССОН (US)
Ян Йоханссон
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us)
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us), Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us)
Publication of RU2011101536A publication Critical patent/RU2011101536A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011101536/15A 2008-06-18 2009-06-17 Усовершенствованные пептидные медиаторы оттока холестерина RU2011101536A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7370808P 2008-06-18 2008-06-18
US61/073,708 2008-06-18

Publications (1)

Publication Number Publication Date
RU2011101536A true RU2011101536A (ru) 2012-07-27

Family

ID=41434685

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011101536/15A RU2011101536A (ru) 2008-06-18 2009-06-17 Усовершенствованные пептидные медиаторы оттока холестерина

Country Status (14)

Country Link
US (1) US8415293B2 (https=)
EP (1) EP2300038A4 (https=)
JP (1) JP2011525181A (https=)
KR (1) KR20110043597A (https=)
CN (1) CN102123722A (https=)
AU (1) AU2009260024A1 (https=)
BR (1) BRPI0915422A2 (https=)
CA (1) CA2727465A1 (https=)
CL (1) CL2010001445A1 (https=)
IL (1) IL209868A0 (https=)
MX (1) MX2010014003A (https=)
PE (1) PE20110106A1 (https=)
RU (1) RU2011101536A (https=)
WO (1) WO2009155366A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123173A1 (en) * 2010-04-28 2013-05-16 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016044177A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
JP2018528257A (ja) * 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
US11840707B2 (en) 2016-05-31 2023-12-12 Institut De Cardiologie De Montreal Co-culture system and method for in vitro assessment of reverse cholesterol transport
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN111848742B (zh) * 2020-07-23 2021-03-23 南京医科大学 一种多肽及其制药用途
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2549529A1 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CA2672131C (en) 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux

Also Published As

Publication number Publication date
AU2009260024A1 (en) 2009-12-23
JP2011525181A (ja) 2011-09-15
KR20110043597A (ko) 2011-04-27
PE20110106A1 (es) 2011-03-02
WO2009155366A3 (en) 2010-04-22
EP2300038A4 (en) 2013-09-04
WO2009155366A2 (en) 2009-12-23
MX2010014003A (es) 2011-02-15
CN102123722A (zh) 2011-07-13
IL209868A0 (en) 2011-02-28
EP2300038A2 (en) 2011-03-30
BRPI0915422A2 (pt) 2017-06-27
US8415293B2 (en) 2013-04-09
US20110190196A1 (en) 2011-08-04
CL2010001445A1 (es) 2012-03-16
CA2727465A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
RU2011101536A (ru) Усовершенствованные пептидные медиаторы оттока холестерина
ES2559927T3 (es) Prevención y reducción de pérdida de sangre y respuesta inflamatoria
JP2004506693A5 (https=)
JP2004536077A5 (https=)
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
RU2006107605A (ru) Пептид (варианты), пара аминокислот, снижающие интенсивность по меньшей мере одного симптома воспалительного состояния, фармацевтическая композиция (варианты), лекарственное средство и фармацевтический набор на их основе
JPH05506252A (ja) 改良トロンビン阻害剤
US12503491B2 (en) MASP inhibitory compounds and uses thereof
JP2011525181A5 (https=)
JP2010513311A5 (https=)
Agerberth et al. Isolation and characterization of a 60-residue intestinal peptide structurally related to the pancreatic secretory type of trypsin inhibitor: influence on insulin secretion.
CN101372512B (zh) 一类抗凝血多肽及其用途
JPWO1997015598A1 (ja) 新規ペプチド
CN106222155A (zh) 一种多肽及其在制备结肠炎及结肠炎相关结直肠癌药物中的应用
EP2089419A2 (en) Inhibition of beta-amyloid aggregation
US6703364B2 (en) Thrombin generation inhibitors
JPH02262595A (ja) ポリペプチド誘導体
JP2015160827A (ja) 急性腎障害に起因する多臓器不全の予防又は治療薬
FI120501B (fi) p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa
WO2021201271A1 (ja) 新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
JP4570402B2 (ja) 中枢機能改善剤
RU2840441C2 (ru) Соединения, ингибирующие masp, и их применения
JP3025672B2 (ja) 新規生理活性ペプチド及びその用途
Pavlíčková et al. 15gag proteinase of myeloblastosis-associated virus: specificity studies with substrate-based inhibitors
JP5755436B2 (ja) 記憶増強剤および記憶力を増強する方法

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20120618